Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)
According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...
Documents similaires
-
Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
par: Claudia Crimi, et autres
Publié: (2023-11-01) -
Economic impact of a more extensive use of FENO testing on the Italian population with asthma
par: Carla Rognoni, et autres
Publié: (2023-06-01) -
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
par: Paolo Solidoro, et autres
Publié: (2022-01-01) -
Critical evaluation of asthma biomarkers in clinical practice
par: Giuseppe Guida, et autres
Publié: (2022-10-01) -
Nasal polyps impact in severe asthma patients: evidences from the SANI
par: Giorgio Walter Canonica, et autres
Publié: (2020-08-01)